CHEMOKINE THERAPEUTICS CLOSES TRANSACTION TO RE-ACQUIRE LICENSING RIGHTS TO CTCE-0214 FROM PPD

Chemokine Therapeutics Corp, a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that it has closed a previously announced transaction with Pharmaceutical Product Development, Inc. ("PPD") and re-acquired its licensing rights on its compound CTCE-0214. PPD will retain an interest in the CTCE-0214 program through potential future milestone payments.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-25-2006/0004368812&EDATE=)